PLx Pharma (PLXP) Financials

$0.00

$0.00 (-4.76%)

As on 14-Jun-2023 09:30EDT

Market cap

$3 Mln

Revenue (TTM)

$5 Mln

P/E Ratio

--

P/B Ratio

0.6

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	4.54	8.21	0.03	0.57	0.75	0.78
Cost of Revenue	4.34	4.81	--	--	--	14.30
Gross Profit	0.20	3.40	0.03	0.57	0.75	0.78
Operating Expenses	64.63	44.19	13.49	14.77	11.71	14.33
Operating Profit (EBIT)	-40.01	-40.79	-13.46	-14.20	-10.96	-15.85
Other Income	24.41	-5.34	-1.44	-5.31	13.00	0.75
Profit before Tax	-27.58	-46.13	-15.21	-20.50	0.90	-16.27
Provision for Tax	-12.43	10.67	1.03	5.55	--	-0.92
Profit after Tax (Net Income)	-15.14	-56.80	-16.24	-26.05	0.90	-15.35
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-27.58	-48.65	-16.95	-34.25	0.90	-15.35

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	26.20	51.68	10.45	1.57	6.44	4.62
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.71	13.08	12.62	10.84	7.21	22.42
Current Liabilities	6.31	11.88	3.54	6.09	4.73	1.82
Total Liabilities	39.54	76.64	26.62	18.50	18.39	28.85

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	3.00	3.17	3.63	4.22	3.52	3.16
Current Assets	30.22	73.48	22.99	14.28	14.87	25.69
Total Assets	39.54	76.64	26.62	18.50	18.39	28.85
Total Debt*	--	--	3.42	5.34	7.19	6.94
Net Current Assets	23.91	61.60	19.44	8.19	10.13	23.87

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-32.12	-12.24	-12.66	-9.50	-13.31
Cash Flow from Investing Activities	--	0.10	-0.10	-0.23	-0.65	11.24
Cash from Financing Activities	--	78.97	20.79	12.64	12.64	26.41
Net Cash Inflow / Outflow	--	46.94	8.45	-0.25	-10.15	24.35

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-173.29	-156.29	-253.66	7.12	-108.44
ROE (%)	-44.42	-182.82	-270.13	-650.23	16.21	-156.72
ROA (%)	-21.83	-110.01	-71.98	-141.25	3.80	-66.81
EBIT Margin (%)	-880.54	-496.95	-44,229.75	-2,511.62	271.18	-2,089.08
Net Margin (%)	-52.30	-1,977.58	1,149.10	549.71	6.52	-1,006.56
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	-31.32	268.73	-0.95	-0.25	-0.03	--
EBIT Growth (%)	30.56	-203.07	5.23	-795.43	112.55	23.71
Net Profit Growth (%)	73.74	-249.76	37.67	-3,006.31	105.84	28.02
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	--	--	--	--	--
Price / Book Value	0.58	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.09	1.97	1.46	0.63	-3.15	1.16
Close Price ($)	0.65	8.01	5.52	4.37	1.53	6.90
High Price ($)	20.18	21.50	7.07	7.41	7.60	14.00
Low Price ($)	0.46	5.20	1.80	1.55	1.00	5.60
Market Cap ($ Cr)	2.53	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	--	0.33	3.40	1.12	1.50
Short term debt to equity ratio	--	0.25	0.06	2.33	0.45	--
Current Ratio	4.79	6.19	6.49	2.34	3.14	14.15
Quick Ratio	4.28	5.98	6.45	--	3.14	14.01
Interest Coverage	-171.58	-7.65	-43.71	-14.27	1.78	-13.96

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	3.06	7.72	--	3.30	2.42	2.49
Asset Turnover	0.07	0.16	0.00	0.03	0.03	0.03
Receivable days	--	14.11	112.13	11.92	9.12	5.74
Inventory Days	--	98.87	--	--	--	4.64
Payable days	--	435.66	--	--	--	36.14
Cash Conversion Cycle	--	-322.68	--	--	--	-25.76

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.